Adenosine Or Derivative Patents (Class 514/46)
-
Publication number: 20090123387Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: January 9, 2009Publication date: May 14, 2009Inventor: Harry A. Dugger, III
-
Publication number: 20090118221Abstract: Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A1 adenosine receptor agonist with a therapeutically effective minimal dose of a beta blocker, calcium channel blocker, or a cardiac glycoside.Type: ApplicationFiled: January 9, 2009Publication date: May 7, 2009Inventors: Luiz Belardinelli, Arvinder Dhalla
-
Publication number: 20090110745Abstract: The present invention provides methods for improving cognitive function, improving mood, and decreasing aggression in a normal adult subject, and in a subject having symptoms characteristic of a neurological disorder, by administration of a nutriceutical formulation of the invention to the subject. The invention additionally features methods of treating neurological disorders, depression, and aggression using nutriceutical formulations. Nutriceutical compositions and formulations for use in the methods of the invention, and kits containing nutriceutical compositions and formulations, are also provided.Type: ApplicationFiled: April 4, 2008Publication date: April 30, 2009Applicant: UNIVERSITY OF MASSACHUSETTS LOWELLInventors: Thomas B. Shea, Amy Y. Chan-Daniels
-
Publication number: 20090110729Abstract: This invention relates to solid oral compositions based on SAMe and/or NADH or their salts in association with calcium oxide and/or calcium hydroxide and a process for obtaining them. This invention also relates to a method for stabilising a solid oral composition based on SAMe and/or NADH or their salts, making use of calcium oxide, calcium hydroxide optionally in association with malic acid, glutamic acid, xylitol, calcium sulphate hemihydrate, magnesium oxide and/or mixtures thereof. This invention also relates to the use of SAMe or its salts in association with calcium oxide and/or calcium hydroxide with the possible further addition of melatonin and/or 1-theanine and/or 1-tryptophan and/or 5-hydroxytryptophan for the treatment of depressive states.Type: ApplicationFiled: September 29, 2008Publication date: April 30, 2009Inventors: DANIELE GIOVANNONE, CARLO DE ANGELIS
-
Publication number: 20090110671Abstract: The present invention has an object to provide a means for durably exerting an action of enhancing collagen-production, and the object is attained by providing a collagen-production enhancer which contains, as an effective ingredient, ?,?-trehalose and/or a saccharide derivative thereof, and by a composition incorporated with the collagen-production enhancer to be used for such purpose.Type: ApplicationFiled: August 3, 2006Publication date: April 30, 2009Inventors: Satomi Miyata, Shimpei Ushio, Kanso Iwaki, Toshio Miyake
-
Patent number: 7521432Abstract: Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging.Type: GrantFiled: April 25, 2007Date of Patent: April 21, 2009Assignee: Wisconsin Alumni Research FoundationInventors: John M. Denu, Kirk G. Tanner
-
Publication number: 20090099103Abstract: The invention relates to a combination comprising an Erb-B and VEGF receptor inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.Type: ApplicationFiled: April 4, 2007Publication date: April 16, 2009Applicant: NOVARTIS AG.Inventors: Gregory Burke, Giorgio Caravatti, Heidi lane, Ronald richard Linnartz, Richard William Versace
-
Publication number: 20090098137Abstract: A combination of an mTOR inhibitor compound with one or more pharmaceutically active agents, for simultaneous, concurrent, separate or sequential use for preventing or treating a proliferative disease.Type: ApplicationFiled: April 5, 2007Publication date: April 16, 2009Applicant: NOVARTIS AGInventors: Gregory Burke, Heidi Lane, Ronald Richard Linnartz, Richard William Versace
-
Patent number: 7517862Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.Type: GrantFiled: August 25, 2004Date of Patent: April 14, 2009Assignee: Idera Pharmaceuticals, Inc.Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
-
Patent number: 7514417Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.Type: GrantFiled: May 19, 2006Date of Patent: April 7, 2009Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Rao Kalla, Thao Perry, Jeff Zablocki, Xiaofen Li
-
Publication number: 20090088403Abstract: The present invention relates to the use of adenosine type 3 receptor (A3R) modulators to modulate serotonin transporter (SERT) function in vivo. In particular, antagonists of A3R can be used to inhibit A3R-dependent upregulation of SERT, for example, as antidepressants.Type: ApplicationFiled: May 7, 2008Publication date: April 2, 2009Inventors: RANDY BLAKELY, Chong-Bin Zhu, William Hewlett
-
Publication number: 20090088404Abstract: Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. major clinical depression) and dysthymia.Type: ApplicationFiled: July 29, 2008Publication date: April 2, 2009Applicant: Methylation Sciences International SRLInventors: Joshua Freedman, Aviva Regev, Nancy Harrison, Robert Miller, David MacDonald
-
Publication number: 20090088366Abstract: The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione.Type: ApplicationFiled: September 24, 2008Publication date: April 2, 2009Applicant: NitroMed, Inc.Inventors: David S. Garvey, Ricky D. Gaston, Inigo Saenz de Tejada, Sang William Tam, Manuel Worcel
-
Publication number: 20090081120Abstract: The present application discloses methods and compositions for increasing patient tolerability during myocardial imaging comprising the administration of doses of caffeine and one or more adenosine A2A receptor agonists to a mammal undergoing myocardial imaging.Type: ApplicationFiled: June 27, 2008Publication date: March 26, 2009Inventors: Hsiao Lieu, Brent Blackburn, Luiz Belardinelli
-
Publication number: 20090082304Abstract: The present invention provides methods of treating hematological malignancies, including multi-drug resistant malignancies, with 8-amino-adenosine and variants thereof. Also encompassed by the present invention is a method of predicting the response of a patient diagnosed with a hematological malignancy to treatment with a nucleoside analog and a method of screening candidate drugs for efficacy in treating hematological malignancies.Type: ApplicationFiled: November 14, 2005Publication date: March 26, 2009Applicants: NORTHWESTERN UNIVERSITY, THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Kulsoom Ghias, Chunguang Ma, Varsha Gandhi, Leonidas C. Platanias, Nancy L. Krett, Steven T. Rosen
-
Patent number: 7504497Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae III, IIIa, and IIIb, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae IIIa and IIIb, which are potent and have a good oral bioavailability.Type: GrantFiled: November 9, 2006Date of Patent: March 17, 2009Assignee: Inspire Pharmaceuticals, Inc.Inventors: James G. Douglass, III, Paul S. Watson, Carl A. Samuelson, Christopher S. Crean
-
Publication number: 20090068125Abstract: This invention relates to a medicament for protecting human mucosal cells from chemotherapy or radiotherapy induced cell death using formulations comprising adenosine or adenosine analogues as a reversible inhibitor of epithelial cell proliferation. The invention also relates to formulations containing adenosine for the prevention of or reduction in mucositis symptoms.Type: ApplicationFiled: January 25, 2006Publication date: March 12, 2009Applicant: HEPTAGEN LTDInventors: Richard Mark Edwards, John Martin Clements
-
Publication number: 20090069267Abstract: The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.Type: ApplicationFiled: July 25, 2008Publication date: March 12, 2009Inventors: Daniel J. Abrams, Raymond Bunch, Tom Anchordoquy, Karen E. Stevens
-
Publication number: 20090053172Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).Type: ApplicationFiled: October 15, 2008Publication date: February 26, 2009Inventors: Christopher Joseph AQUINO, Pek Yoke CHONG, Maosheng DUAN, Wieslaw Mieczyslaw KAZMIERSKI
-
Publication number: 20090053168Abstract: The invention provides compositions and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and compositions may further include an antiproliferative compound.Type: ApplicationFiled: July 17, 2008Publication date: February 26, 2009Inventors: Richard Rickles, Margaret S. Lee
-
Publication number: 20090048203Abstract: This invention relates to compounds of Formula (I): and their use in the treatment of bacterial infections.Type: ApplicationFiled: October 13, 2005Publication date: February 19, 2009Inventors: Marta Cavero-Tomas, Madhu Gowravaram, Hoan Huynh, Haihong Ni, Suzanne Stokes
-
Publication number: 20090047243Abstract: The invention features compositions and methods employing combinations of an A2A receptor agonist and a PDE inhibitor for the treatment of a B-cell proliferative disorder, e.g., multiple myeloma.Type: ApplicationFiled: July 17, 2008Publication date: February 19, 2009Inventors: Richard Rickles, Laura Pierce, Margaret S. Lee
-
Publication number: 20090042831Abstract: 5?-methylthioadenosine (MTA), its pharmaceutically acceptable salts and/or prodrugs may be used in the prevention and/or treatment of autoimmune diseases, such as, for example, Multiple Sclerosis (MS), as well as in the prevention and/or treatment of transplant rejection.Type: ApplicationFiled: March 17, 2005Publication date: February 12, 2009Applicant: Proyecto de Biomedicina Cima, S.L.Inventors: Pablo Villoslada Diaz, Matias Avila Zaragoza, Beatriz Moreno Bruna, Fernando Corrales Izquierdo, Carmen Berasain Lasarte, Elena Ruiz Garcia-Trevijano
-
Patent number: 7488720Abstract: Disclosed are novel compounds that are A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, diseases related to release of nonesterified fatty acids, and myocardial infarction.Type: GrantFiled: October 11, 2006Date of Patent: February 10, 2009Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Xiaofen Li, Jeff Zablocki
-
Publication number: 20090022813Abstract: It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a) a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.Type: ApplicationFiled: June 20, 2008Publication date: January 22, 2009Applicant: N.V. NUTRICIAInventor: Robert J. J. HAGEMAN
-
Patent number: 7479485Abstract: Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A1 adenosine receptor agonist with a therapeutically effective minimal dose of a beta blocker, calcium channel blocker, or a cardiac glycoside.Type: GrantFiled: October 28, 2005Date of Patent: January 20, 2009Assignee: CV Therapeutics, Inc.Inventors: Luiz Belardinelli, Arvinder Dhalla
-
Publication number: 20090018101Abstract: S-Adenosyl-L-methionine analogs of formula (I) wherein R comprises a carbon-carbon double bond, carbon-oxygen double bond, carbon-sulfur double bond, carbon-nitrogen double bond, a carbon-carbon triple bond, carbon-nitrogen triple bond or an aromatic carbocyclic or heterocyclic system in ?-position to the sulfonium center, X— is an organic or inorganic anion carrying one or more negative charges, Z is —CR1R2—, —O—, —S— or —NR3— and R1, R2 and R3 are independently selected from H, D and C1-C12 alkyl. Also disclosed are complexes of the compound with a methyltransferase, pharmaceutical compositions comprising the same, methods for modifying biomolecule using the compound, and methods for detecting sequences specific methylation of biomolecules using the compound.Type: ApplicationFiled: October 11, 2007Publication date: January 15, 2009Applicants: RWTH AACHEN, INSTITUTE OF BIOTECHNOLOGYInventors: Elmar Weinhold, Christian Dalhoff, Saulius Klimasauskas, Grazvydas Lukinavicius
-
Publication number: 20090012036Abstract: Stable compositions of defined non-racemic diastereomeric ratios of S-adenosyl-L-methionine, methods for their synthesis and methods for their uses are described. The compositions according to the invention are very stable and are valuable for use as active constituents in pharmaceutical compositions.Type: ApplicationFiled: September 20, 2008Publication date: January 8, 2009Inventor: Rolland F. Hebert
-
Publication number: 20090012035Abstract: Disclosed are conjugates comprising a dendrimer and a ligand, which is a functionalized congener of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily, for example, wherein the functionalized congener is an A1 adenosine receptor agonist having a purine nucleoside moiety and a functional group at the N6 position of the purine nucleoside moiety, wherein the functional group has the formula (I): N6H—Ar1—CH2—C(?O)NH—R1 (I), wherein Ar1 and R1 as defined herein. Also disclosed are pharmaceutical compositions, methods of treating various diseases, and a diagnostic method employing such conjugates.Type: ApplicationFiled: June 20, 2008Publication date: January 8, 2009Applicants: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPA, INSERM U.311Inventors: Kenneth A. Jacobson, Yoonkyung Kim, Athena Klutz, Beatrice Hechler, Christian Gachet
-
Patent number: 7468357Abstract: A method for the treatment of a host, and in particular, a human, infected with hepatitis B virus (HBV) is provided that includes administering an effective amount of a ?-L-nucleotide, optionally in combination therapy with other drugs for the treatment of HBV or human immuno-deficiency virus (HIV).Type: GrantFiled: June 12, 2001Date of Patent: December 23, 2008Assignee: Emory UniversityInventors: Raymond F. Schinazi, Jean-Pierre Sommadossi, Gilles Gosselin, Jean-Louis Imbach
-
Publication number: 20080312160Abstract: A therapeutic method for treating intestinal damage, enteritis, diarrhea, or a combination thereof caused by a C. difficile is provided. The method includes administration to a patient in need thereof an effective amount of an A2A adenosine receptor agonist, optionally in combination with an effective amount of a stable glutamine derivative, e.g., alanyl-glutamine.Type: ApplicationFiled: April 9, 2008Publication date: December 18, 2008Inventors: Richard L. Guerrant, Joel M. Linden, Cirle A. Warren, Gail W. Sullivan, Timothy L. Macdonald
-
Publication number: 20080312180Abstract: Disclosed herein are compositions and methods for the treatment of skeletal muscle and/or the protection of skeletal muscle against injury. The adenosine A3 receptor has been identified as a new therapeutic target for the treatment of skeletal muscle. Adenosine A3 receptor agonists are used treat subjects with skeletal muscle ischemia and reperfusion (I/R) injuries, individuals with skeletal muscle disorders, and individuals suffering from skeletal muscle injury resulting from physical exertion.Type: ApplicationFiled: March 25, 2008Publication date: December 18, 2008Applicants: Institute of Enviromental MedicineInventors: Bruce Tsan-Tang Liang, Edward John Zambraski
-
Patent number: 7465715Abstract: Individuals suffering from multiple sclerosis may be treated by administration of an A3 adenosine receptor agonist (A3RAg), such as APNEA, AB-MECA, IB-MECA or Cl-IB-MECA. The A3RAg is preferably administered orally with a pharmaceutically acceptable carrier.Type: GrantFiled: December 23, 2004Date of Patent: December 16, 2008Assignee: Can-Fite Biopharma, Ltd.Inventors: Pnina Fishman, Sara Bar Yehuda, Lea Madi
-
Patent number: 7462604Abstract: A hair growth promotor which is an ethanol or aqueous ethanol preparation comprising, as active ingredients for a hair growth promotor, (A) at least one compound selected from fatty acids having a chain length of an odd number of carbon atoms, the derivatives of the fatty acids, aliphatic alcohols having a chain length of an odd number of carbon atoms and the derivatives of the aliphatic alcohols and (B) at least one selected from 6-benzylaminopurine and/or the derivatives thereof represented by the following Formula (I), wherein it further comprises (C) at least one of polyglycerin fatty acid esters and (D) at least one of sorbitan fatty acid esters: in Formula (I), R1 and R2 are defined. The hair growth promotor can have an excellent hair growth effect and can provide an excellent stabilization effect at low temperature and can provide good feeling having no stickiness.Type: GrantFiled: September 29, 2004Date of Patent: December 9, 2008Assignees: Lion Corporation, Sansho Seiyaku Co., Ltd.Inventors: Sumi Kaneda, Nobuyasu Satou, Masatoshi Hasegawa, Masahiro Motono
-
Publication number: 20080300214Abstract: The invention provides methods for treating or suppressing marihuana usage, withdrawal, or dependence involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, uridine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.Type: ApplicationFiled: August 10, 2005Publication date: December 4, 2008Inventors: Scott E. Lukas, Perry F. Renshaw
-
Publication number: 20080300213Abstract: The present invention provides the use of an A3 adenosine receptor agonist (A3AR agonist) for the preparation of a pharmaceutical composition for the treatment of a mammal subject having osteoarthritis (OA), as well as to a method for the treatment of OA in a mammal subject, the method comprises administering to said subject in need of said treatment an amount of an A3AR agonist, the amount being effective to treat or prevent the development of OA. Preferred but not exclusive A3AR agonists in accordance with the invention are IB-MECA and Cl—IB-MECA. The A3AR agonist may be administered in combination with another drug, such as, Methotrexate (MTX). The invention also provides pharmaceutical compositions for treatment of osteoarthritis comprising an amount of an A3AR agonist.Type: ApplicationFiled: November 29, 2006Publication date: December 4, 2008Inventor: Pnina Fishman
-
Publication number: 20080293666Abstract: The invention provides compounds of formula (I) and salts thereof: R1-L-R2—B wherein R1, L, R2, and B have any of the values defined herein, as well as compositions comprising such compounds, and therapeutic methods comprising the administration of such compounds or salts. The compounds block siderophore production in bacteria and are useful as antibacterial agents.Type: ApplicationFiled: December 6, 2006Publication date: November 27, 2008Applicant: Regents of the University of MinnesotaInventors: Courtney Aldrich, Ravindranadh Venkata Somu
-
Publication number: 20080287390Abstract: The invention provides the use of an optionally hydroxyl-protected 4-hydroxy or hydroperoxy-3,5-dioxopyrazolidine or an equivalent wherein a pyrazolidine ring attached oxygen is replaced by a sulphur, or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in drug therapy or prophylaxis. Additionally, the invention provides a method of combating HIV infection which comprises administering to an HIV-infected patient a T-lymphocyte growth suppressing agent, preferably a pyrazolidinol, in an amount sufficient to suppress T-lymphocyte growth in said patient for a period sufficient to reduce the T-lymphocyte concentration in lymph nodes in said patient.Type: ApplicationFiled: January 14, 2008Publication date: November 20, 2008Applicant: A-Viral ASInventors: Enok Tjotta, Jo Klaveness
-
Patent number: 7452870Abstract: The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.Type: GrantFiled: November 4, 2005Date of Patent: November 18, 2008Assignee: Inspire Pharmaceuticals, Inc.Inventors: José L. Boyer, James G. Douglass, III, Sammy R. Shaver
-
Publication number: 20080274997Abstract: A fluid bed granulation process for manufacturing non-hygroscopic, stable granulates containing a water-soluble salt of S-adenosylmethionine is described. Said process comprises: a) the simultaneous, sequential or alternate dispersion of at least a solution of a water-soluble salt of SAMe (A) and of a solution of a coating agent (B), on a fluid bed granulation carrier (C) and b) the fluid bed granulation of the mixture. Granulates obtainable by said process and solid oral pharmaceutical forms obtainable by said granulates are disclosed.Type: ApplicationFiled: July 10, 2008Publication date: November 6, 2008Applicant: CHEMISTRY AND HEALTH INTERNATIONAL BVInventors: CARLO CANTABENE, PAOLO MAGRI, MICHELE MULLER
-
Publication number: 20080267861Abstract: This invention relates to methods for performing myocardial perfusion imaging for diagnosing and characterizing coronary artery disease using an intravenous (IV) bolus injection of regadenoson while the patient is undergoing sub-maximal exercise.Type: ApplicationFiled: January 3, 2008Publication date: October 30, 2008Applicant: CV THERAPEUTICS, INC.Inventors: Hsiao D. Lieu, Gregory Thomas
-
Publication number: 20080254010Abstract: This document provide materials and methods for treating patients infected with a spore-forming bacteria and materials and methods for preventing development of Clostridium difficile-associated disease.Type: ApplicationFiled: March 12, 2008Publication date: October 16, 2008Inventors: Joseph Myron Sasser, Katrina Shoemaker Cousin
-
Patent number: 7435724Abstract: The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.Type: GrantFiled: November 21, 2005Date of Patent: October 14, 2008Assignee: Inspire Pharmaceutical, Inc.Inventors: James G. Douglass, III, Benjamin R. Yerxa, Sammy R. Shaver, Ward M. Peterson, Edward G. Brown, Christopher S. Crean, José L. Boyer
-
Publication number: 20080249060Abstract: Disclosed are compounds, compositions and methods for treating hepatitis C virus infections.Type: ApplicationFiled: May 19, 2008Publication date: October 9, 2008Inventors: Christopher Don Roberts, Natalia B. Dyatkina
-
Patent number: 7429570Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.Type: GrantFiled: March 21, 2007Date of Patent: September 30, 2008Assignee: Hopital Sainte-JustineInventors: Ernest G. Seidman, Yves Theoret
-
Patent number: 7427606Abstract: The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A2A adenosine receptor agonist. If no anti-pathogenic agent is known the A2A agonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.Type: GrantFiled: December 2, 2004Date of Patent: September 23, 2008Assignee: University of Virginia Patent FoundationInventors: Joel M. Linden, Kenneth Brayman, Gail W. Sullivan
-
Patent number: 7425546Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.Type: GrantFiled: March 22, 2007Date of Patent: September 16, 2008Assignee: Hopital Sainte-JustineInventors: Ernest G. Seidman, Yves Theoret
-
Patent number: 7425547Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula IB as follows: and pharmaceutically acceptable prodrugs and salts thereof, where R, R1, R13, R14, W, W2, W3, Y and Z are as defined herein.Type: GrantFiled: September 30, 2003Date of Patent: September 16, 2008Assignee: Genelabs Technologies, Inc.Inventors: Christopher Don Roberts, Natalia B. Dyatkina
-
Publication number: 20080219927Abstract: A stable composition useful for myocardial perfusion imaging contains one or more 2-alkynyladenosine derivatives; and a solvent which is made up of water and hydroxypropyl-?-cyclodextrin.Type: ApplicationFiled: January 16, 2008Publication date: September 11, 2008Inventors: Ajit B. Thakur, Dianne D. Zdankiewicz, Hsun-Wen Hsu, James F. Castner, James E. Anderson
-
Publication number: 20080221060Abstract: Use of compounds of general formula (A) as medicaments is described, in particular for the treatment of pain or inflammation; wherein: (I) when X=OH, R2=NH2, R5=CH2OH, R6=H, R1 is C5-C6 alkoxy, OCH2Cyclopropyl, O-(2,2,3,3-tetrafluoro-cycloButyl), phenoxy, substituted phenoxy, OCH2CH2OH, or OCH2CHF2, (5-indanyl)oxy, C1, C2, C5, or C6 alkylamino, (R) or (S)-sec-Butylamino, C5 or C6 cycloalkylamino, exo-norbornane amino, (N-methyl, N-isoamylamino), phenylamino, phenylamino with either methoxy or fluoro substituents, a C2 sulfone group, a C2 alkyl group, a cyano group, a CONH2 group, or 3,5-dimethylphenyl; or when X=H, R2=NH2, R5=CH2OH, R6=H, R1 is n-hexyloxy; or (II) when X=OH, R1=H, R5=CH2OH, R6=H, R2 is NMe2, N-(2-isopentenyl), piperazinyl, (N-Me, N-benzyl), (N-Me, N—CH2Ph(3-Br)), (N-Me, N—CH2Ph(3-CF3)), or (N-Me, N-(2-methoxyethyl)), or OCH2Cyclopentyl; or (III) when X=OH, R5=CONHR3, R6=H: R1 is H, R3 is an isopropyl group, and R2 is either NH2 or a methylamino group (NHMe) or an isoamyl group (CH2CH2CHMe2);Type: ApplicationFiled: March 4, 2005Publication date: September 11, 2008Inventors: Martyn Pritchard, Jacqueline Ouzman, Edward Savory, Giles Brown